Author:
Yang Tingting,Kang Lihua,Li Dan,Song Yanqiu
Abstract
Immunotherapy is a developing treatment for advanced breast cancer. Immunotherapy has clinical significance for the treatment of triple-negative breast cancers and human epidermal growth factor receptor-2 positive (HER2+) breast cancers. As a proved effective passive immunotherapy, clinical application of the monoclonal antibodies trastuzumab, pertuzumab and T-DM1 (ado-trastuzumab emtansine) has significantly improved the survival of patients with HER2+ breast cancers. Immune checkpoint inhibitors that block programmed death receptor-1 and its ligand (PD-1/PD-L1) have also shown benefits for breast cancer in various clinical trials. Adoptive T-cell immunotherapies and tumor vaccines are emerging as novel approaches to treating breast cancer, but require further study. This article reviews recent advances in immunotherapy for HER2+ breast cancers.
Reference102 articles.
1. Targeted therapeutic options and future perspectives for HER2-positive breast cancer;Wang;Signal transduction targeted Ther,2019
2. HER2: biology, detection, and clinical implications;Gutierrez;Arch Pathol Lab Med,2011
3. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer;Kauraniemi;Am J Pathol,2003
4. The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells;Sahlberg;Mol Oncol,2013
5. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial;Eggermont;Lancet Oncol,2020
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献